Simultaneous administration of more than one vaccine did not impair immunogenicity.

The first study enrolled 1,283 healthy girls aged 11-18 years at 48 U.S. centers. The researchers randomized the participants to one of six different treatment schemes: HPV vaccine only at months 1, 2, 3, and 6; Tdap only at month 0 followed by Tdap at month 0 followed by HPV vaccine 6 months after the final dose, when one dose was given in combination with one or two of the other vaccines, were noninferior to the responses to the HPV vaccine given by itself. The recipients of two or more simultaneously administered vaccines also had similar incidence rates for adverse events.

The second study examined concomitant administration of an investigational, 13-valent, conjugated pneumococcal vaccine and the tetravalent, seasonal influenza vaccine of 2007-2008 in 1,106 healthy adults aged 50-59 years. The first study enrolled 1,283 healthy girls aged 11-18 years at 48 U.S. centers. The researchers randomized the participants to one of six different treatment schemes: HPV vaccine only at months 0, 1, and 6; HPV with Tdap at month 0 followed by HPV only at months 1 and 6; HPV with the meningococcal vaccine at month 0 followed by HPV only at months 1 and 6; and HPV with the meningococcal vaccine at month 0 followed by HPV only at months 1 and 6; HPV with Tdap at month 0 followed by HPV only at months 1 and 6.

Dr. Robert W. Freck Jr., professor of pediatrics at Cincinnati Children's Hospital Medical Center, and his associates randomized subjects to receive either the pneumococcal and flu vaccines together at month 0 followed by placebo at month 1, or the flu vaccine and placebo at month 0 followed by the pneumococcal vaccine at month 1. One month after vaccination, the immune responses to both vaccines in people who received them simultaneously fell within the prespecified noninferiority limit, compared with the responses in people who received the two vaccines 1 month apart, Dr. Freck reported. Simultaneous administration also resulted in similar rates of local and systemic reactions compared with giving the vaccines 1 month apart.

Disclosures: Dr. Wheeler has received research support from GlaxoSmithKline, Merck (which markets the HPV vaccine Gardasil), and Roche/Molecular Systems. Dr. Freck's study was funded by Wyeth, which developed the pneumococcal vaccine; he had no other disclosures.

Simultaneous administration of more than one vaccine did not impair immunogenicity.